PCI Biotech to Dissolve After Halting All Operations

OSLO, NORWAY – February 23, 2026 – PCI Biotech Holding ASA, a once-promising Norwegian biopharmaceutical company, has announced its intention to dissolve and delist from the Euronext Oslo Børs. The board's proposal comes after a complete cessation of all research and development activities, marking the final chapter for a firm that spent years developing a novel drug delivery technology.

An Extraordinary General Meeting (EOGM) has been scheduled for March 16, 2026, where shareholders will vote on the proposed dissolution. The company's board cited "no longer any operational activity in the Company, nor is it expected that it will resume such activity" as the primary reason for the drastic measure. The wholly-owned subsidiary, PCI Biotech AS, is undergoing a parallel dissolution process.

The Unraveling of a Promising Cancer Therapy

At the heart of PCI Biotech's journey was its proprietary Photochemical Internalisation (PCI) technology. This platform, which originated from research at the Oslo University Hospital, was designed to enhance the efficacy of drugs by using a photosensitizer, fimaporfin, and light to deliver therapeutic agents directly into target cells. The company pursued several applications, but its most advanced program, fimaCHEM, was its flagship hope.

The fimaCHEM program focused on improving chemotherapy outcomes for bile duct cancer, a rare but aggressive malignancy with limited treatment options. The company was advancing a pivotal study called RELEASE, which investors and the medical community watched closely. However, the program's trajectory was abruptly altered in January 2022.

The critical turning point came not from a failure within PCI Biotech's own trial, but from a major breakthrough by competitors. Results from the TOPAZ-1 study demonstrated a significant survival benefit using a combination of immunotherapy and standard chemotherapy, establishing a new global standard of care for advanced biliary tract cancer almost overnight. Faced with this new reality, PCI Biotech concluded that the landscape had changed too dramatically to continue the RELEASE study, forcing a strategic pivot and the first major crack in the company's foundation.

A Cascade of Setbacks and Dwindling Cash

Following the termination of its lead program, PCI Biotech announced it would reallocate its resources to its other platform technologies: fimaVACC, a vaccine potentiation technology, and fimaNAc, a nucleic acid delivery system. The company also initiated a new project in 2022, Photochemical Lysis (PCL), aimed at improving viral vector manufacturing.

Despite the strategic shift, the company struggled to regain momentum. In August 2025, another blow landed when the company halted the development of its PCL technology. The decision was made after internal evaluations showed "insufficient progress towards demonstrating improved yield," leading the company to deem the project's risk profile unacceptable.

By this point, the company's financial precarity was becoming undeniable. The interim report for the first half of 2025, published in August, revealed a cash position of just NOK 13.6 million, enough to sustain operations only into the fourth quarter of that year. The report explicitly noted that this critical liquidity situation cast "significant doubt about the company’s ability to continue as a going concern."

The final months were marked by a desperate search for a lifeline. An external evaluation of a new bioprocessing technology by an undisclosed party was the company's last hope, but in early January 2026, PCI Biotech announced this effort had concluded "without prospects for further collaboration." With all R&D operations officially discontinued and its cash reserves depleted, the board initiated a process to evaluate a structured wind-up, culminating in today's announcement.

The Final Chapter for Shareholders and Assets

For shareholders who have been on this volatile journey, the proposed dissolution represents the end of the line. The delisting from Euronext Oslo Børs, where the stock has traded since 2018, will remove it from the public market, and the subsequent liquidation will determine what, if anything, is left for investors.

The board's recommendation to delist was based on the "non-existent operational activity and limited asset base," concluding that the company is "no longer suitable for listing on a public trading platform." The liquidation process will involve settling all debts and liabilities, after which any remaining assets would be distributed to shareholders.

A key question revolves around the fate of the company's intellectual property. PCI Biotech holds several patents, including a European patent for its fimaNAc mRNA delivery technology valid until 2039 and a US patent for its fimaVACC technology protecting it until 2036. These assets, while not sufficient to sustain the company, could hold value for other pharmaceutical firms. The detailed resolutions for the EOGM will outline the board's plan for these assets, which will likely involve an attempt to sell the IP portfolio to maximize any potential return for stakeholders during the wind-down.

A Cautionary Tale in the Biotech Arena

PCI Biotech's demise serves as a stark reminder of the inherent risks and brutal realities of the biopharmaceutical industry. The sector is characterized by long development timelines, immense capital requirements, and a high rate of failure. Even promising technology can be rendered obsolete by faster or more successful competitors, as was the case with the fimaCHEM program.

The company's story unfolds against a backdrop of a challenging funding environment that has seen a record number of biotech bankruptcies and layoffs globally in recent years. For smaller, research-focused firms like PCI Biotech, securing the continuous, substantial funding needed to navigate clinical trials and regulatory hurdles is a monumental challenge.

Even being an integrated member of the Oslo Cancer Cluster, a respected research and industry hub, was not enough to insulate the company from its operational and financial challenges. The fall of PCI Biotech is a cautionary tale for investors, highlighting the extreme volatility of biotech stocks and the thin line between a breakthrough and a shutdown. Its journey from a promising innovator to a company preparing for liquidation underscores the unforgiving nature of an industry where only a few scientific bets ultimately pay off.